Serotonin Reuptake Inhibitors and Cardiovascular Disease

Belcher, Philip R.; Drake-Holland, Angela J.; Noble, Mark I. M.

doi:10.2174/1567270052774368

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with SSRIs leads to depletion of serotonin in platelets [ 53 , 54 ], this in turn results in lower activity of platelets [ 55 ] and reduced aggregation [ 56 ]. This supports the hypothesis that SSRIs may reduce the risk of myocardial infarction [ 57 - 59 ] as lower platelet serotonin content may lead to less serotonin release during platelet activation at an intra-coronary stenosis [ 60 ].…”

Section: Discussionsupporting

confidence: 80%

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Hansen

Hanash

Rasmussen

et al. 2009

Trials

View full text Add to dashboard Cite

Background: The prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome.

show abstract

Section: Discussionsupporting

confidence: 80%

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Hansen

Hanash

Rasmussen

et al. 2009

Trials

View full text Add to dashboard Cite

show abstract

“…Second, the antiplatelet effects of these drugs should be monitored and compared to patients not taking SSRIs. It is now possible reliably to measure platelet function in whole blood 24 hours after sampling; this would allow remote testing of a large number of patients [111,112].…”

Section: The Futurementioning

confidence: 99%

Serotonin Reuptake Inhibitors and Cardiovascular Disease

Belcher¹,

Drake-Holland²,

Noble³

2008

VDP

Self Cite

View full text Add to dashboard Cite

A Prospective Study on Effect of Fluoxetine on Primary Hemostasis of Patients Having Major Depressive Disorder

NARENDRANATH

et al. 2022

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: The objectives of the study were to study the effect of fluoxetine on bleeding time, clotting time and platelet count of depressed patients. Methods: Patients diagnosed with major depressive disorder were included in the study to fulfill a sample size of 60. Before starting the treatment with fluoxetine, laboratory tests were done which included bleeding time, clotting time, and platelet count. Patients were requested to return for follow-up after 4 weeks of treatment and the laboratory tests were repeated. All the study end point analysis was analyzed based on per-protocol population. Continuous variables were expressed as mean and standard deviations, paired t-test was used for within group comparison and unpaired t-test was used for between group comparisons. p<0.05 was considered to be significant. For categorical variable, frequency and percentage were calculated. For continuous variable, that is, bleeding time, clotting time, and platelet count, mean and standard deviation were calculated. Results: At the end of 4 weeks, it was observed that there was a significant increase in bleeding time from 1.35±0.08 min to 1.46±0.08 min**. Similarly, there was a significant increase in clotting time from 3.30±0.15 min to 3.38±0.15 min**. It was also observed that there was a significant decrease in platelet count from 3.07±0.67 lakh cells/cu mm to 2.86±0.63 lakh cells/cu mm**. Conclusion: Fluoxetine has shown to increase bleeding time, clotting time, and decrease platelet count. Hence, fluoxetine induced risk of bleeding and its cardio protective action has to be considered while individualizing therapy in management of depression.

show abstract

Serotonin Reuptake Inhibitors and Cardiovascular Disease

Cited by 3 publications

References 1 publication

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Serotonin Reuptake Inhibitors and Cardiovascular Disease

A Prospective Study on Effect of Fluoxetine on Primary Hemostasis of Patients Having Major Depressive Disorder

Contact Info

Product

Resources

About